Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015

Torres-Bondia, Francisco; Batlle, Jordi de; Galván, Leonardo; Butı́, Miquel; Barbé, Ferrán; Piñol‐Ripoll, Gerard

doi:10.1186/s12889-022-13217-6

Cited by 27 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, by cumulative effect, the number of prevalent chronic drug users increased very slightly from 4.2% in 2017 to 4.4% in 2020 (p < 0.0001). Even though the sharp increase of the absolute number of incident chronic consumers in 2020 has no explanation to this day, this overall increasing trend in PPIs consumption is comparable to that observed in other European countries such as the United Kingdom or Spain, and confirms the global overconsumption of PPIs [23,24].…”

Section: Discussionsupporting

confidence: 60%

(De)Prescribing of proton pump inhibitors: what has changed in recent years? an observational regional study from the French health insurance database

Gendre

Julie

Artarit³

et al. 2022

BMC Prim. Care

View full text Add to dashboard Cite

Background Proton pump inhibitors (PPIs) are one of the most widely prescribed drug classes in the community and at hospital. The significant misuse of PPIs requires the implementation for a deprescribing strategy. Numerous studies aiming at evaluating the impact of deprescribing interventions have been set up, implying a precisely known evolution of consumption of PPIs in the population studied without intervention. The main objective of the study was to study overall changes in PPI prescribing and deprescribing in a regional population of chronic consumers without intervention, according to health insurance databases. Methods This historical cohort study was based on the French National Health Data System databases. All adult patients living in the Pays de la Loire area and covered by the French National Health Insurance and who had at least one reimbursement for a PPI dispensing between 01 October 2016 and 31 December 2020 were included. Only chronic consumer patients were included, defined as patients who has had PPI dispensed for 3 consecutive months with a temporal coverage of at least 80%. Patients under 18 years of age and patients who received parenteral PPIs only were excluded. Results The percentage of chronic treatment discontinuation in 2017 was 12.5% and remained stable to reach 12.4% in 2020. The number of new chronic patients increased from year to year to reach 77,222 patients in 2020, with an increasing rate of 1.2 to 2% between 2017 and 2020. The prevalent patient population increased from year to year to reach 167 751 patients in 2020, with an increasing rate of 4.2 to 4.4% between 2017 and 2020. Regarding the initiation of PPI therapy, in 2020, 87.1% of treatment initiations were done by general practitioners. They renewed 2,402,263 prescriptions (89.3%) between 2017 and 2020. Conclusions This study shows a stagnation over the last 4 years in the deprescribing of chronic PPI treatments in a French region despite the information on their inappropriate use reported by national agencies and in the literature with increasing frequency. This reinforces the interest of setting up a deprescribing project.

show abstract

Section: Discussionsupporting

confidence: 60%

(De)Prescribing of proton pump inhibitors: what has changed in recent years? an observational regional study from the French health insurance database

Gendre

Julie

Artarit³

et al. 2022

BMC Prim. Care

View full text Add to dashboard Cite

show abstract

“…In recent years, there have been concerns about the increased prevalence of PPI use 12. Despite the increased prevalence of PPI use in previous studies,2 5 6 13 28 findings of this study show a decrease in the rate of PPI prescriptions, PPI use and expenditure.…”

Section: Discussioncontrasting

confidence: 68%

“…Similarly, in Denmark, the prevalence of PPI use increased by fourfold between 2002 and 2013, reaching 7.4% in 2014 10. Moreover, in Spain, the annual prevalence of PPI showed an upward trend from 11.3% (2002) to 18.0% (2015) 13. In addition, in Australia, the prevalence of PPI use was 12.6% in 2016 14.…”

Section: Introductionmentioning

confidence: 93%

Evolution of proton pump inhibitor prescribing from 2017 to 2021 at 14 secondary and tertiary hospitals in China：a multicentre cross-sectional study

Zeng

Yuan²,

Chen

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to describe the trend in prescribing proton pump inhibitor (PPI) use and expenditure in both secondary and tertiary hospitals in China between 2017 and 2021.DesignMulticentre cross-sectional survey.SettingChina, 14 medical centres, January 2017 to December 2021.Participants537 284 participants who were treated with PPI in 14 medical centres of China, between January 2017 and December 2021 were included.Main outcomes and measuresThe rate of PPI prescriptions, the defined daily doses (DDDs), DDDs/1000 inhabitants per day (DDDs/TID) and expenditure were analysed and plotted to demonstrate changes in prescription PPI use and expenditure.ResultsFor both outpatient and inpatient settings, the rate of PPI prescribing decreased from 2017 to 2021. In outpatient settings, decreased slightly from 3.4% to 2.8%, however, in inpatient settings, showed a progressive decrease from 26.7% to 14.0%. The overall rate of injectable PPI prescriptions for inpatients decreased significantly from 21.2% to 7.3% between 2017 and 2021. Decreased trends in usage of oral PPI were observed (from 280 750 DDDs to 255 121 DDDs) between 2017 and 2021. However, usage of injectable PPI showed a significantly decrease from 191 451 DDDs to 68 806 DDDs from 2017 to 2021. In terms of DDDs/TID of PPI for inpatients decreased dramatically from 52.3 to 30.2 for the past 5 years. Expenditure on oral PPI decreased slightly from ¥1.98 million (Chinese currency Renminbi ‘yuan’) to ¥1.23 million for the past 5 years, whereas expenditure on injectable PPI showed a marked decrease from ¥2.61 million to ¥0.94 million. There was no statistical difference in both PPI use and expenditure between secondary and tertiary hospitals during the study period.ConclusionsDecreased PPI use and expenditure were observed among secondary and tertiary hospitals over the past 5 years (2017–2021).

show abstract

“…A recent cohort study found that antibodies of AIG were associated with increased gastric cancer risk, being strongest in non-cardia locations [ 30 ]. There was also speculation of more antibiotics and proton-pump inhibitor (PPI) therapy use in women than men [ 31 ], which alter the gut microbiome potentially eliciting an inflammatory response. Altogether, the higher risk for autoimmunity and medication-induced inflammatory states in young women than men may play a role in the sex-specific differences in primary NCGC incidence seen in this study.…”

Section: Discussionmentioning

confidence: 99%

Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000–2018: A Time-Trend Analysis Using the USCS Database

Abboud

Burch

et al. 2023

Cancers

View full text Add to dashboard Cite

Introduction: Although the global incidence of non-cardia gastric cancer (NCGC) is decreasing, there are limited data on sex-specific incidence in the United States. This study aimed to investigate time trends of NCGC from the SEER database to externally validate findings in a SEER-independent national database, and to further assess trends among subpopulations. Methods: Age-adjusted incidence rates of NCGC were obtained from the SEER database from 2000 to 2018. We used joinpoint models to calculate average annual percentage change (AAPC) to determine sex-specific trends among older (≥55 years) and younger adults (15–54 years). Using the same methodology, findings were then externally validated using SEER-independent data from the National Program of Cancer Registries (NPCR). Stratified analyses by race, histopathology, and staging at diagnosis were also conducted in younger adults. Results: Overall, there were 169,828 diagnoses of NCGC from both independent databases during the period 2000–2018. In SEER, among those <55 years, incidence increased at a higher rate in women (AAPC = 3.22%, p < 0.01) than men (AAPC = 1.51%, p = 0.03), with non-parallel trends (p = 0.02), while a decreasing trend was seen in both men (AAPC = −2.16%, p < 0.01) and women (AAPC = −1.37%, p < 0.01) of the ≥55 years group. Validation analysis of the SEER-independent NPCR database from 2001 to 2018 showed similar findings. Further stratified analyses showed that incidence is disproportionately increasing in young non-Hispanic White women [AAPC = 2.28%, p < 0.01] while remaining stable in their counterpart men [AAPC = 0.58%, p = 0.24] with non-parallel trends (p = 0.04). This pattern was not observed in other race groups. Conclusion: NCGC incidence has been increasing at a greater rate in younger women compared to counterpart men. This disproportionate increase was mainly seen in young non-Hispanic White women. Future studies should investigate the etiologies of these trends.

show abstract

Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015

Cited by 27 publications

References 33 publications

(De)Prescribing of proton pump inhibitors: what has changed in recent years? an observational regional study from the French health insurance database

(De)Prescribing of proton pump inhibitors: what has changed in recent years? an observational regional study from the French health insurance database

Evolution of proton pump inhibitor prescribing from 2017 to 2021 at 14 secondary and tertiary hospitals in China：a multicentre cross-sectional study

Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000–2018: A Time-Trend Analysis Using the USCS Database

Contact Info

Product

Resources

About